Lock the editor's digest lock for free
Roula Khalaf, the editor of FT, selects his favorite story in this week's newsletter.
Astrazeneca has a big blow to Prime Minister Kir's government Prime Minister, has a 450 million -pound British vaccine manufacturing plant after fighting for several months with British officials for the project. I canceled it.
According to those who are familiar with this issue, British officials have filed a revised offer for a revised financial support for sites close to Liverpool this month this month this month.
Starmer's Labor Government first sought to reduce the public funds provided in the Speke project from about £ 90 million to 40 million pounds last summer.
“After a long -term discussion with the government, we are no longer pursuing a planned investment in Speke,” Astrazeneca stated on a statement on Friday.
“Compared to the previous government proposal, several factors have affected this decision, such as timing and reduction of the final offer.”
The new factory was trying to create next -generation influenza vaccines and help Britain to recover more in future pandemics.
The existing Speke site, as ASTRAZENECA, the largest company in the UK due to market capitalization, continues to produce and supply influenza vaccines.
This decision was a few days after Prime Minister Rachel Reeves tried to position Britain as a very attractive place for life science companies to invest in major speeches on growth.
Priority and Reeves have been criticizing business last year for tax budgets for 40 billion pounds and other measures, including the rights of more powerful workers.
Former conservative Prime Minister Jeremy Hunt, a former UK offer to the Pharmaceutical Group, contains up to £ 70 million pounds to develop an existing Astrazeneca vaccine in Speke. R & D support from the health security institution contained £ 20 million.
Hunt, who announced a contract with a large fanfare last March, told Financial Times that Astrazenka's decision was a “large -scale goal by the government.”
“The production of high -end vaccines is a big opportunity to keep up with excessive dependence on the value chain of the value chain.” “I signed this contract in 2023, personally intervened to make this transaction, and repented that the government dropped the ball.”
The government states: “As Astrazeneca's first proposed investment configuration has reduced the number of government subsidies, and unfortunately, all government subsidies need to show the value of taxpayers. It is impossible to achieve a solution despite the wide range of activities from government officials.
“Astrazenka is involved in government work to develop a new industrial strategy.”
One of the knowledge of the relationship tells the government that he was “deep frustrated” to the government, and Spark is only one of the tensions in a wider crash in the industry over drug prices and the future of life science investment.
People close to Pharmaceuticals Group said that they are considering other possible manufacturing sites in new vaccine factories because they have abandoned the Speke plan.
In November, Astra Seneca plans to invest $ 3.5 billion in R & D and manufacture in the United States, the world's largest pharmaceutical market, which produces 44 % of the company's sales.
Pascal Soriot, the highest executive officer of Astrazeneca, said at that time that investment reflected the “quality of business environment, talent and innovation skills.”
The company plans to have $ 1.5 billion in Singapore, and last week, pledged $ 560 million in Canada.
People with business knowledge stated that the decision on the Speke facilities would not affect Astraazenka's other investment in the UK.
SPEKE's decision comes when the United States provides a very attractive privilege to companies planning to invest in manufacturing, such as states' infrastructure investment, loans and subsidies for research and development.
President Donald Trump has called for “all the businesses in the world” to “make your product in the United States.”
“We will give you one of the minimum taxes of all countries on the earth,” Trump said in a video stream of Davos's World Economic Forum last week. “But if you don't make a product in the United States, if it's your privilege, it's very simple, you have to pay tariffs.”
Trump says he wants to reduce corporate tax from 21 % to 15 %.
